Merck KGaA says its once-daily pill, pimicotinib, designed to inhibit the overexpression of CSF-1, a protein contributing to tenosynovial giant cell tumor (TGCT) growth, showed ” statistically significant” success in clinical trials. Of 100 TGCT patients treated with the drug, 54% showed an objective response after 25 weeks, compared with 3.2% of those on a placebo. TGCT, a rare, nonfatal tumor affecting joints, is currently treated with surgery, but the tumors often regrow, introducing the risk of complications and impaired joint function.
News – Bradford Health Services reports 2023 data breach, compromising patient and staff data – teiss
Bradford Health Services suffered a data breach in 2023 leading to a compromise of patient and staff data.
